A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma

10.1371/journal.pone.0066361PLoS ONE86-POLN

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma : Updated Overall Survival, Safety, and Subgroups

Introduction: The phase III RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma (ENDEAVOR) trial showed significantly improved progression-free survival and overall survival (OS) with carfilzomib (56 mg/m) and dexamethasone (Kd56) versus bortezomib and Kd56 (Vd) in patients with relapsed or refractory multiple myeloma (RRMM). We report updated OS and safety data after 6 months of additional follow-up. Patients and Methods: Patients with RRMM (1-3 previous lines of therapy) were randomized 1:1 to Kd56 or Vd. Median OS was estimated using the Kaplan-Meier method; OS was compared between treatment groups using Cox proportional hazards models. Results: As of July 19, 2017, median follow-up was 44.3 months for Kd56 and 43.7 months for Vd. Median OS was 47.8 months (Kd56) versus 38.8 months (Vd; hazard ratio, 0.76; 95% confidence interval, 0.633-0.915). OS was longer with Kd56 versus Vd within age and cytogenetic subgroups, and according to number of previous lines of therapy, previous bortezomib exposure, previous lenalidomide exposure, and lenalidomide-refractory status. Exposure-adjusted incidences per 100 patient-years of adverse events (AEs) were 1352.07 for Kd56 and 1754.86 for Vd; for Grade ≥3 AEs, these values were 162.31 and 175.90. Conclusion: With median follow-up of approximately 44 months, clinically meaningful improvements in OS were observed with Kd56 versus Vd, including in all subgroups examined. The Kd56 safety profile was consistent with previous analyses. In this updated analysis of patients with relapsed/refractory multiple myeloma (RRMM) from the RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma (ENDEAVOR) trial, clinically meaningful overall survival improvements continue to be observed with carfilzomib 56 mg/m and dexamethasone (Kd56; n = 464) versus bortezomib and dexamethasone (n = 465), including in key patient subgroups. With longer-term data, the favorable benefit-risk profile of Kd56 continues to support its use as a standard-of-care in RRMM

MicroRNA in chronic lymphocytic leukemia [2]

10.1056/NEJMc053266New England Journal of Medicine3545524-525NEJM

"Micro"-managing the MiRNome in SzS

10.1182/blood-2010-05-285189Blood11671021-1022BLOO

P53 abnormalities and potential therapeutic targeting in multiple myeloma

10.1155/2014/717919BioMed Research International201471791

The Molecular Biology of Multiple Myeloma

10.1002/9781444318531.ch11Molecular Hematology: Third Edition127-13

Matematica e matematici nella Scuola Normale di Pisa, 1862-1918

La Scuola normale Superiore di Pisa, riformata dopo l'Unità d'Italia, fu per 50 anni luogo di formazione di gran parte dei ricercatori italiani nel campo dell'analisi e della fisica matematica e fornì anche molti insegnanti ben preparati per la scuola italiana

Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia [1]

10.1016/j.leukres.2004.11.017Leukemia Research296719-720LERE

MicroRNA: Important player in the pathobiology of multiple myeloma

10.1155/2014/521586BioMed Research International201452158